checkAd

     254  0 Kommentare Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference

    Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on November 18th and 19th.

    The company will showcase ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

    Following is a list of abstracts that will be presented at the meeting.

    Scientific Poster Presentations

    Poster Number

     

    Title & Presenter

     

    Day & Time

     

    Location

    A19

     

     

    HLA allele-specific loss of heterozygosity detection
    using augmented exome capture approach

    Presenter: Rachel Marty Pyke, Ph.D.

     

    November 18:
    12:30 PM – 3:00 PM

     

    Back Bay

    B18

     

     

    Exome scale liquid biopsy monitoring of putative
    neoantigens and genomic biomarkers in patients
    on anti-PD-1 therapy in squamous cell carcinoma of
    the head and neck

    Presenter: Charles Abbott, Ph.D.

     

    November 19:
    4:30 PM – 7:00 PM

     

    Back Bay

    Personalis will also be exhibiting during the conference (Exhibit # 10). Representatives will be available to answer questions about the company’s cancer immunogenomics services.

    About Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, …

    Schreibe Deinen Kommentar

    Disclaimer